Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number 50 copies/mL was 4.1 months (95 CI 3.54.6) in non-coinfected patients and 3.9 months (95 CI 3.34.5) in coinfected patients (hazard ratio 1.039, 95 CI 0.7611.418, P0.766, log-rank test). The risk of developing new grade 34 hepatic adverse events was significantly higher in coinfected patients (hazard ratio 1.779, 95 CI 1.1232.817, P0.009). The two groups of coinfected and non-coinfected patients had similar rates of interruption of any baseline drug (hazard ratio 1.075, 95 CI 0.6491.781, P0.776) and of raltegravir (hazard ratio 1.520, 95 CI 0.6713.447, P0.311). Few AIDS-defining events and deaths occurred. Viroimmunological response to regimens based on raltegravir and other recent anti-HIV inhibitors is not negatively affected by coinfection with HBV or HCV. Liver toxicity, either pre-existing or new, is more common in coinfected patients, but with no increased risk of treatment interruption.